Menu
Washingtoner
  • Home
  • Health
  • Technology
  • Artificial Intelligence
  • Real Estate
  • Entertainment
  • Longevity
  • Business
  • Software
Washingtoner

Myosana Therapeutics Raises $5 Million in Seed Funding
Washingtoner/10205303

Trending...
  • Spokane: City Seeks Feedback on Future Land Use Map
  • City of Spokane Launches 'Emergency Streets' Pilot Program
  • Medcurity Introduces a Better Way for Healthcare and Its Vendors to Build Trust
SEATTLE--(BUSINESS WIRE)--Myosana Therapeutics, Inc., pioneer of a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases, today announced the completion of a seed funding round totaling over $5 million led by investor John Ballantyne, Ph.D. The capital will go toward developing Myosana's platform with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025.

"Built on decades of expertise in neuromuscular diseases, Myosana's muscle-specific non-viral gene therapy platform is poised to change the way patients are treated for neuromuscular and cardiac diseases," said Ballantyne, Cofounder and former longtime CSO of Biologics CDMO-Aldevron, and a Founder of therapeutic delivery system developer Agathos. "Myosana's progress building on the platform's promising in vivo data is an essential next step. I'm excited to partner with the company as it pushes ahead toward a therapy that will reach patients and improve their lives."

New investments from the Muscular Dystrophy Association and Parent Project Muscular Dystrophy (PPMD) rounded out the seed round, building on capital from original Myosana investor CureDuchenne Ventures and early investor PPMD a year later.

More on Washingtoner
  • Spokane: City to Temporarily Close Pedestrian Access to Browne St Viaduct
  • West Coast Self-Storage Manages Airport Money Saver in Tumwater, Washington
  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
  • Tacoma: Applicants Sought for the Audit Advisory Board
  • Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th

Completion of this major funding round comes just as Myosana has appointed its new CEO, Dr. Matthew Lumley. A board member since 2021, Lumley is a physician scientist who has spent nearly two decades in academic medicine and drug development, cultivating expertise in translational medicine and early clinical development in complex pediatric diseases. Lumley is also the father of a son with Duchenne muscular dystrophy. In his role on Myosana's Board of Directors, Lumley has been intimately involved in raising seed funding and advancing the platform.

"Dr. Ballantyne's expertise in the nucleic acid production and delivery spaces builds credibility in our approach. His investment, alongside our nonprofit partners, will go directly to platform optimization and the identification of a development candidate for Duchenne muscular dystrophy in the next 18-24 months," said Lumley. "As proof of principle for the platform, success in treating Duchenne would open up opportunities for Myosana to target a large range of neuromuscular and cardiac diseases."

Alongside his role as CEO of Myosana, Lumley is a Venture Partner at Medicxi, a life sciences-focused venture capital firm where he is involved in the formation and financing of biotechnology companies across the full drug development continuum. His recent roles include Senior Director of Rare Disease Clinical Development at Moderna and Medical Director of Rare Diseases at Pfizer.

About Myosana Therapeutics

Myosana Therapeutics, Inc., has pioneered a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases. Based on this platform, the company is developing new gene therapies that will potentially transform progressive neuromuscular and cardiac diseases, increasing longevity and improving quality of life. Myosana's first clinical candidate from the platform will be delivery of full-length dystrophin as a therapy for Duchenne muscular dystrophy.

More on Washingtoner
  • Mach One Reports Launches Voice-First Software That Builds Inspection Reports On Site
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • Most Indiana Plane Crashes Happen Away from the State's Major Airports
  • L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
  • Mom Era, Still That Girl: Family Art Tees 25% Off

Myosana's esteemed leadership team includes cofounders Stan Froehner, Ph.D., and Nick Whitehead, Ph.D., both internationally known experts in neuromuscular disease from the University of Washington, whose decades-long careers are marked by significant milestones. Dr. Froehner discovered the syntrophin proteins in muscle's dystrophin complex and developed several pre-clinical treatments for muscular dystrophy. Dr. Whitehead has uncovered mechanisms of muscle weakness in Duchenne muscular dystrophy and developed Myosana's innovative non-viral platform. The platform overcomes the significant limitations of viral vector-delivered gene therapy for muscle disease by providing targeted muscle delivery, large gene capacity, repeat dosing, and immune neutrality.

To learn more and follow Myosana's progress toward its first clinical development candidate, visit us at www.myosanatherapeutics.com.

Contacts

Kara Stephens-Weaver
407-765-1185
kara.stephens-weaver@precisionvh.com
Show All News | Disclaimer | Report Violation

1 Comment
1000 characters max.

  • unity asset store.:
    Build real-time 3D projects for various industries across games, animation, automotive, architecture, and more with Unity Asset Store. Start creating with Unity today!
Latest on Washingtoner
  • The Social Capital Revolution Comes to Phoenix!
  • Spokane: Flags Lowered for Mayor Tim Verzal
  • Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
  • FBI/DoW plot uncovered to hurt Trump/Vance through encouraged "widespread" cybersecurity breaches and racketeering theft of $80m in USDA payments
  • City of Tacoma Aligns Parking Rates and Facilities for Downtown Parking Network Effective October 13
  • Bettingbladet releases H1 2026 report on the Swedish online gambling market
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • Tacoma: Application for 2027 Community Arts Projects Funding Now Available
  • Haven Treatment Center Now In-Network Partnership with ComPsych, Expanding Access to Youth Health
  • Tacoma: OMWBE Certification 201 Workshop on September 28
  • Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
  • Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Pebble Photo Booths Brings Modern Photo Experiences to Vancouver, Washington
  • Spokane: Flags at Half-Staff in Remembrance of 9/11 Victims
  • Haven Treatment Center Now In-Network with First Choice, Expanding Access to Youth Health
  • Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
_catLbl0 _catLbl1

Popular on Washingtoner

  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support - 239
  • Diginyze eCommerce ERP Module Creates Single Source of Truth for Enterprise Operations - 156
  • Continuous You Foundation Opens Applications For A 100-year Artist Grant - 140
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses - 131
  • Tacoma: Applications Now Being Accepted for a Position on the Planning Commission - 127
  • Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs - 127
  • DuoKey launches the World's First Agentic Crypto Agility Platform - 118
  • Tacoma: Hylebos Bridge Closed Today for Maintenance Work - 117
  • Dr. Pen Official Introduces Advanced Microneedling Technology for Precision Skincare at Home
  • Marti Reeder Ranked Among Washington State's Top Real Estate Brokers by RealTrends Verified

Similar on Washingtoner

  • Can Government Operate Better Through Innovation?
  • West Coast Self-Storage Manages Airport Money Saver in Tumwater, Washington
  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
  • Notaron Expands Online Notarization Access Following Wisconsin Approval
  • Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
  • The Social Capital Revolution Comes to Phoenix!
  • Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute